Century Therapeutics (IPSC) Net Cash Flow (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Net Cash Flow data on file, last reported at -$11.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 71.22% year-over-year to -$11.3 million in Q1 2026; TTM through Mar 2026 was -$907000.0, a 115.51% decrease from a year earlier, with the FY2025 full-year figure at $3.8 million, down 68.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$11.3 million, down from $6.3 million in the prior quarter.
• Over the last five years, Net Cash Flow for IPSC reached as high as $69.6 million in Q1 2022 and fell as low as -$27.1 million in Q4 2022.
• Historically, Net Cash Flow has averaged -$260529.4 across 5 years, with a median of -$1.4 million in 2022.
• Across the five-year window, Net Cash Flow surged 221.99% in 2024 and sank 1183.79% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$27.1 million in 2022, then surged by 70.53% to -$8.0 million in 2023, then jumped by 172.42% to $5.8 million in 2024, then advanced by 9.2% to $6.3 million in 2025, then slumped by 278.27% to -$11.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$11.3 million in Q1 2026, $6.3 million in Q4 2025, and -$913000.0 in Q3 2025.